Personal information

No personal information available

Activities

Collapse all

Works (3)

Clearance of residual genome editing components used for ex vivo genome-editing of allogeneic cell therapy products

Cytotherapy
2024-11 | Journal article
DOI: 10.1016/j.jcyt.2024.06.005
Contributors: Alex Chialastri; Hunter Hoffman; Damien Fink; Jennifer L. Dashnau
Source: check_circle
Crossref

A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies

Cytotherapy
2023-01 | Journal article
DOI: 10.1016/j.jcyt.2022.08.001
Contributors: Jennifer L. Dashnau; Qiong Xue; Monica Nelson; Eric Law; Lan Cao; Derek Hei
Source: check_circle
Crossref

Development of an induced pluripotent stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products

Cytotherapy
2022-07 | Journal article
DOI: 10.1016/j.jcyt.2022.02.005
Contributors: Liam Chung; L. Amarin Cogburn; Lina Sui; Jennifer L. Dashnau
Source: check_circle
Crossref
How many people are using ORCID?